netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Formulary Chapter 9: Nutrition and blood - Full Chapter  Expand sub section  Electrolytes and water  Expand sub section  Intravenous sodium
Sodium Chloride

Sodium Chloride 0.9%(normal saline)
Injection: 5ml, 10ml & 20ml
IV infusion: 100ml, 250ml, 500ml & 1000ml
Irrigation: 1000ml & 3000ml

Sodium Chloride 0.18%
IV infusion: 500ml

Sodium Chloride 0.45%
IV infusion: 500ml

Sodium Chloride1.8%
IV infusion: 500ml

Sodium Chloride 2.7%
IV infusion: 500ml

Sodium Chloride 5%
IV infusion: 500ml

Sodium Chloride 30%
Injection: 10ml

Sodium Chloride and Glucose Intravenous Infusion

IV infusion: 0.9%/5% 500ml
IV infusion: 0.18%/4% 500ml & 1000ml
IV infusion: 0.18%/10% 500ml
Infusion: 0.45%/5% 500ml

Hartmann's solution (compound sodium lactate)
View adult BNF View SPC online

Infusion: 500ml, 1000ml  Expand sub section  Intravenous glucose  Expand sub section  Intravenous potassium  Expand sub section  Bicarbonate and lactate to top  Expand sub section  Water
 Non Formulary Items
Ringer's Solution for Injection

View adult BNF View SPC online
Non Formulary
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Track Changes
Display tracking information
click to search
Link to adult BNF
click to search
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHS England

Traffic Light Status Information

Status Description


Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   


These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

Green +

Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  


These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.